Table 1 Baseline patient characteristics.
Variable | Ā | Calcification | Non-calcification | p value a |
|---|---|---|---|---|
All patients | Ā | 17 (48.6%) | 18 (51.4%) | Ā |
Age (years) | ā„ā65 | 8 (47.1%) | 7 (38.9%) | 0.738 |
| Ā | <ā65 | 9 (52.9%) | 11 (61.1%) | Ā |
Sex | Male | 9 (52.9%) | 12 (66.7%) | 0.500 |
| Ā | Female | 8 (47.1%) | 6 (33.3%) | Ā |
BVZ treatment | New diagnosis | 10 (58.8%) | 10 (55.6%) | >ā0.999 |
| Ā | Recurrence | 7 (41.2%) | 8 (44.4%) | Ā |
WHO grade | 3 | 8 (47.1%) | 9 (50.0%) | >ā0.999 |
| Ā | 4 | 9 (52.9%) | 9 (50.0%) | Ā |
IDH-1 mutation | Yes | 4 (26.7%) | 4 (23.5%) | >ā0.999 |
| Ā | No | 11 (73.3%) | 13 (76.5%) | Ā |
MGMT protein expression | Present | 10 (66.7%) | 10 (58.8%) | 0.708 |
| Ā | Absent | 5 (33.3%) | 7 (41.2%) | Ā |
Number of BVZ cycles | ā„ā23 | 13 (76.5%) | 6 (33.3%) | 0.018 |
| Ā | <ā23 | 4 (23.5%) | 12 (66.7%) | Ā |
BCNU wafer implantation | Yes | 8 (47.1%) | 9 (50.0%) | >ā0.999 |
| Ā | No | 9 (52.9%) | 9 (50.0%) | Ā |
Extent of resection | ā„ā90% | 6 (35.3%) | 10 (55.6%) | 0.315 |
| Ā | <ā90% | 11 (64.7%) | 8 (44.4%) | Ā |
